Releaf Dispensary Ltd Announces UK Cannabis Survey: 97% See Quality of Life Gains

2 months ago

Largest UK Active Medical Cannabis Patient Survey shows 97% improvement in quality of lifeThe Findings from Releaf, shows major improvements…

Releaf Dispensary Ltd Announces UK Cannabis Survey: 97% See Quality of Life Gains

2 months ago

Largest UK Active Medical Cannabis Patient Survey shows 97% improvement in quality of lifeThe Findings from Releaf, shows major improvements…

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

2 months ago

Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)King of Prussia, Pennsylvania--(Newsfile Corp. -…

Establishment Labs to Present at Jefferies London Healthcare Conference

2 months ago

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,…

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

2 months ago

Net proceeds will be applied to debt reduction, advancing Organon’s ongoing deleveraging efforts Positions Organon for future investment in growth…

TruBridge Announces Third Quarter 2025 Results

2 months ago

MOBILE, Ala.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ: TBRG), a leading provider of revenue cycle management and healthcare technology solutions for rural and…

Dr. Patrick Doherty: Advancing Spine Care With Innovation, Compassion and Patient Empowerment

2 months ago

BOSTON, MASSACHUSETTS / ACCESS Newswire / November 7, 2025 / Dr. Patrick Doherty, Associate Professor of Neurosurgery at Yale, is…

UniDoc to Exhibit at ANCI 2025 in Bologna, November 12-14

2 months ago

VANCOUVER, BC / ACCESS Newswire / November 7, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company") will attend…

Tizona Therapeutics Presents Clinical Translational Evidence of Dual Innate and Adaptive Immune Activation with TTX-080, a First-in-Class HLA-G Antagonist, in Patients with Advanced Solid Tumors at SITC 2025

2 months ago

Enrolling patients in ongoing randomized Phase 1b trial in MSS metastatic colorectal cancer, evaluating TTX-080 in combination with cetuximab +…

Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide

2 months ago

Results, presented at ObesityWeek® 2025, showed patients receiving NG101 saw 40% reduction in nausea incidence and 67% reduction in vomiting…